Saili Medical released its 2026 interim report on August 27. First-half operating revenue was 343 million yuan, down 41.3 percent year on year. Net loss attributable to the parent company was 47.84 million yuan, narrowing from a loss of 56.12 million yuan in the same period last year. Net loss attributable to the parent company after deducting non-recurring items was 47.52 million yuan, compared with a loss of 70.6 million yuan a year earlier. Net operating cash flow was negative 34.78 million yuan, an improvement of 56.1 percent year on year. Second-quarter operating revenue was 161 million yuan, down 45.6 percent year on year, and net loss attributable to the parent company was 30.32 million yuan, narrowing from a loss of 41.8 million yuan in the same period last year. The company said that under the impact of the National Healthcare Security Administration's DRG and DIP payment reforms and centralized procurement policies, operating revenue declined and industry profit margins came under pressure. The company is optimizing its business structure and strengthening cost control and receivables management to improve profitability and cash flow.
Wuhan Thalys Med Tech Co LtdDRG/DIP reforms and centralized procurement cut revenue and pressured margins.
